Result card

  • CUR18: Is intravenous immunoglobulin (IVIG) therapy a new, innovative mode of care, an add-on to or modification of a standard mode of care or replacement of a standard mode of care?
English

Is intravenous immunoglobulin (IVIG) therapy a new, innovative mode of care, an add-on to or modification of a standard mode of care or replacement of a standard mode of care?

Authors: Antonio Migliore, Tapani Keranen, Sinikka Sihvo

Internal reviewers: Kristian Lampe

IVIG therapy is proposed as a new mode of care for Alzheimer’s disease including Mild Cognitive Impairment. Current management involves the treatment of cognitive, non-cognitive and behavioural symptoms. Non-pharmacological treatment includes social support, increasing assistance with day-to-day activities, information and education, carer support groups, community dementia teams, home nursing and personal care, community services such as meals-on-wheels, befriending services, day centres, respite care and care homes {89}. At the current stage of development, it is not possible to state whether the IVIG therapy will be proposed alone or in combination with the current management solutions.

Critical
Completely
Migliore A et al. Result Card CUR18 In: Migliore A et al. Health Problem and Current Use of the Technology In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 30 October 2020]. Available from: http://corehta.info/ViewCover.aspx?id=267

References